You are here

gene editing

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Pharma Voice

Thu, 05/15/25 - 10:43 am

Editas Medicine

Federal appeals court sends CRISPR-Cas9 patent case back to patent office for reconsideration

UC Berkeley News

Wed, 05/14/25 - 09:59 am

J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus

Fierce Biotech

Tue, 05/13/25 - 11:10 am

Stylus Medicine

CRISPR Therapeutics sees 80% fall in LDL, triglycerides after in vivo liver editing

Fierce Biotech

Wed, 05/7/25 - 11:23 am

CRISPR Therapeutics

LDL cholesterol

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

Clinical Trials Arena

Tue, 04/15/25 - 11:11 am

Verve Therapeutics

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Stock Titan

Mon, 04/14/25 - 09:44 am

Verve Therapeutics

clinical trials

cardiovascular disease

Verve gets FDA green light to expand base editing trial into US

BioPharma Dive

Tue, 03/25/25 - 10:22 am

Verve Therapeutics

clinical trials

Why Prime Medicine Stock Was Climbing Higher This Week

Motley Fool

Thu, 03/20/25 - 09:51 pm

alpha-1 antitrypsin deficiency

Prime sets sights on liver, lung disease as next target for its gene editing tech

BioPharma Dive

Tue, 03/18/25 - 11:04 pm

alpha-1 antitrypsin deficiency

Vertex axes Verve gene editing pact amid shift in R&D priorities

Fierce Biotech

Thu, 02/27/25 - 10:13 am

Vertex Pharmaceuticals

Verve Therapeutics

Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV

Clinical Trials Arena

Thu, 02/20/25 - 11:51 am

Precision Biosciences

clinical trials

4 companies to watch in the accelerating gene editing race

Pharma Voice

Thu, 01/2/25 - 11:18 am

AlgenScribe SAS

Broken String Biosciences

CorriXR Therapeutics

Intellia’s gene editing therapy shows early potential in rare heart condition

Clinical Trials Arena

Mon, 11/18/24 - 11:30 am

Editas, changing course again, looks to partner lead CRISPR therapy

BioPharma Dive

Tue, 10/22/24 - 11:45 am

Editas Medicine

sickle cell disease

beta thalassemia

Editas cashes in on portion of Vertex gene editing licensing agreement for $57M

Fierce Biotech

Fri, 10/4/24 - 09:24 am

Editas Medicine

Vertex Pharmaceuticals

Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy

Fierce Pharma

Tue, 09/24/24 - 09:51 pm

Vertex Pharmaceuticals

Gene Editing Startup Tome Struggles to Stay Afloat Just Months After Launching

BioSpace

Fri, 08/23/24 - 11:11 am

Tome Bioscience

Vertex, Orum partner on safer pre-treatment for gene meds

Pharmaphorum

Wed, 07/17/24 - 11:48 am

Orum Therapeutics

Beacon lights up with $170m for retinal disease gene therapy

Pharmaphorum

Wed, 07/3/24 - 11:21 am

Beacon Therapeutics

X-linked retinitis pigmentosa

retinal diseases

First-of-its-kind Intellia data suggest CRISPR drug could be given more than once

BioPharma Dive

Wed, 06/26/24 - 10:00 am

Intellia Therapeutics

transthyretin amyloidosis

Pages